The AAPS Journal

, 9:E371 | Cite as

Preparation and ocular pharmacokinetics of ganciclovir liposomes

  • Yan Shen
  • Jiasheng Tu


Ophthalmic liposomes of ganciclovir (GCV) were prepared by the reverse phase evaporation method, and their ocular pharmacokinetics in albino rabbits were compared with those obtained after dosing with GCV solution. The in vitro transcorneal permeability of GCV liposomes was found to be 3.9-fold higher than that of the solution. After in vivo instillation in albino rabbits, no difference was found in the precorneal elimination rate of GCV from liposome vs solution dosing. The aqueous humor concentration-time profiles of both liposomes and solution were well described by 2-compartmental pharmacokinetics with first-order absorption. The area under the curve of the aqueous humor concentration-time profiles of GCV liposomes was found to be 1.7-fold higher than that of GCV solution. Ocular tissue distribution of GCV from liposomes was 2 to 10 times higher in the sclera, cornea, iris, lens, and vitreous humor when compared with those observed after solution dosing. These results suggested that liposomes may hold some promise in ocular GCV delivery.


Ganciclovir liposomes precorneal clearance ocular pharmacokinetics 


  1. 1.
    Mar E, Cheng Y, Huang Y. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother, 1983;24:518–521.PubMedGoogle Scholar
  2. 2.
    Martin J, Dvorack C, Smee D, Matthews T, Verheyden J, 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med Chem. 1983;26:759–761.PubMedCrossRefGoogle Scholar
  3. 3.
    Cantrill H, Henry K, Melroe N, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results, Ophthalmology, 1989;96:367–374.PubMedGoogle Scholar
  4. 4.
    Markham A, Faulde D. Ganciclovir: an update of its therapeutic use in cytomegalovirus infection, Drugs. 1994;48:455–460.PubMedCrossRefGoogle Scholar
  5. 5.
    Maudgal P, De Clercq K, Descamps J, Missotten L. Topical treatment of experimental herpes simplex keratouveitis with 2′-O-glycylacyclovir, a water-soluble ester of acyclovir, Arch Opthalmol. 1984;102:140–142.Google Scholar
  6. 6.
    Hughes P, Mitra A. Effect of acylation on the ocular disposition of acyclovir. II. Corneal permeability and anti-HSV 1 activity of 29-esters in rabbit epithelial keratitis. J Ocul Pharmacol. 1993;9:299–309.PubMedCrossRefGoogle Scholar
  7. 7.
    Drew W. Is combination antiviral therapy for CMV superior to monotherapy? J Clin Virol. 2006;35:485–488.PubMedCrossRefGoogle Scholar
  8. 8.
    Wiltink E, Stekkinger P, Brakenhoff J, Danner S. Determination of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in biological fluids by reverse-phase high pressure liquid chromatography. Pharm Weekbl Sci. 1987;9:261–264.PubMedGoogle Scholar
  9. 9.
    Choonara Y, Pillay V, Carmichael T, et al. An in vitro study of the design and development of a novel doughnut-shaped minitablet for intraocular implantation. Int J Pharm. 2006;310:15–24.PubMedCrossRefGoogle Scholar
  10. 10.
    Law S, Huang K, Chiang C. Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption. J Control Release. 2000;63:135–140.PubMedCrossRefGoogle Scholar
  11. 11.
    Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press, 1966.Google Scholar
  12. 12.
    Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA. 1978;75:4194–4198.PubMedCrossRefGoogle Scholar
  13. 13.
    Wu P. The characterization and biodistribution of cefoxitin-loaded liposomes. Int J Pharm. 2004;271:31–39.PubMedCrossRefGoogle Scholar
  14. 14.
    Law S, Hung H. Properties of acyclovir-containing liposomes for potential ocular delivery. Int J Pharm. 1998;161:253–259.CrossRefGoogle Scholar
  15. 15.
    Durrani A, Farr S, Kellaway I. Influence of molecular weight and formulation pH on the precorneal clearance rate of hyaluronic acid in the rabbit eye. Int J Pharm. 1995;118:243–250.CrossRefGoogle Scholar
  16. 16.
    McSharry J, McDonough A, Olson B, et al. Inhibition of ganciclovir-susceptible and-resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin Diagn Lab Immunol. 2001;8:1279–1281.PubMedCrossRefGoogle Scholar
  17. 17.
    McCalden T, Levy M. Retention of topical liposomal formulation on the cornea. Experientia. 1990;46:713–715.PubMedCrossRefGoogle Scholar
  18. 18.
    Pleyer U, Lutz S, Jusko W, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci. 1993;34:2737–2742.PubMedGoogle Scholar
  19. 19.
    Elsayed M, Abdallah O, Naggar V, et al. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm. 2006;322:60–66.PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  1. 1.Department of PharmaceuticsChina Pharmaceutical UniversityNanjingChina

Personalised recommendations